Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML) With a Focus on Patients Treated With Rydapt (Midostaurin) in Helsinki and Uusimaa Hospital District

ID
Name
CPKC412AFI02
Description
This was a non-interventional, retrospective registry study, utilizing electronic health record (EHR) data collected in the hospital district of Helsinki and Uusimaa (HUS). Real-world health care resource utilization (HCRU) of AML patients was characterized.
Trial arms
Trial start
2020-09-24
Estimated PCD
2021-01-26
Trial end
2021-01-26
Status
Completed
Treatment
Midostaurin
Midostaurin was administered in two different dosing options. Either as 2x25mg daily or 2x50mg daily.
Arms:
Midostaurin
Other names:
Rydapt
Size
81
Primary endpoint
Number of patients initiating midostaurin treatment
throughout the study, approximately 5 years
Eligibility criteria
Inclusion Criteria: * Patients who are diagnosed with acute myeloid leukemia (ICD-10 C92.0) during 1.1.2016-30.6.2020 * Adult (18 years or older) at the time of first diagnosis * Health registry data is available and accessible * Resident in the hospital district HUS at the time of index diagnosis Exclusion Criteria: - AML patients with no treatment information
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 81, 'type': 'ACTUAL'}}
Updated at
2022-11-08

1 organization

1 product

1 indication

Product
Midostaurin
Indication
Acute Myeloid Leukemia
Organization
Novartis Pharmaceuticals